Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Year ended 31st March, 2026

Nature of Filing / Announcement: Outcome of Board Meeting pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015

Audit Opinion:

Unmodified opinion from the statutory auditors, Maheshwari & Gupta, Chartered Accountants (FRN:006179C). No audit qualifications or reservations. Statement on Impact of Audit Qualifications not required.

Key Financial Highlights [Amount in Lakhs except EPS]:

Standalone Results (Year ended 31st March, 2026):

  • Revenue from Operations: ₹2,839.52
  • Total Income: Not Specified
  • EBITDA: Not Specified
  • Net Profit: ₹278.60
  • EPS (Basic and Diluted): ₹1.71
  • Other Equity: ₹529.05
  • Cash and Cash Equivalents: ₹6.38
  • Debt: Not Specified

Standalone Results (Quarter ended 31st March, 2026):

  • Revenue from Operations: ₹756.56
  • Total Income: Not Specified
  • EBITDA: Not Specified
  • Net Profit: ₹21.22
  • EPS (Basic and Diluted): ₹0.13

Prior Period Comparison (Year ended 31st March, 2025):

  • Revenue from Operations: ₹3,340.22
  • Net Profit: (Loss) ₹(125.42)
  • EPS: ₹(0.34)

Segment-wise Performance:

The company operates in two reportable segments: Pharma Division and Chemicals Division.

For the Year ended 31st March, 2026:

  • Pharma Division:
  • Segment Revenue: ₹1,896.33
  • Segment Result (Profit before tax and interest): ₹235.90
  • Chemical Division:
  • Segment Revenue: ₹943.19
  • Segment Result (Profit before tax and interest): ₹94.69

For the Quarter ended 31st March, 2026:

  • Pharma Division:
  • Segment Revenue: ₹111.48
  • Segment Result (Loss before tax and interest): ₹(30.63)
  • Chemical Division:
  • Segment Revenue: ₹645.08
  • Segment Result (Profit before tax and interest): ₹70.15

Statement of Assets and Liabilities as at 31st March, 2026 [Amount in Lakhs]:

  • Total Assets: ₹4,284.81
  • Non-current assets: ₹698.53 (Property, Plant & Equipment: ₹693.50; Other Non-Current Assets: ₹5.03)
  • Current assets: ₹3,586.26 (Inventories: ₹399.97; Trade receivables: ₹2,758.60; Cash and cash equivalents: ₹6.38; Bank balances other than cash equivalents: ₹326.26; Other Current Assets: ₹95.05)
  • Total Equity and Liabilities: ₹4,284.81
  • Equity: ₹2,156.43 (Equity Share Capital: ₹1,627.38; Other Equity: ₹529.05)
  • Current liabilities: ₹2,068.93 (Trade Payables: ₹1,706.04; Other Financial Liabilities: ₹20.18; Other Current Liabilities: ₹20.18; Provisions: ₹40.71)

Statement of Cash Flows for the year ended 31st March, 2026 [Amount in Lakhs]:

  • Net cash flows from operating activities: ₹(60.49)
  • Net cash flows from investing activities: ₹113.74 (Payment for PPE: ₹(20.05); Proceeds from sale of PPE: ₹133.79)
  • Net cash flows from financing activities: ₹253.86 (Increase in Borrowings: ₹254.87; Finance cost: ₹(1.01))
  • Net increase in cash and cash equivalents: ₹307.11
  • Cash and cash equivalents at end of year: ₹332.64

Corporate Actions:

Not Specified

Other Significant Information:

  • Disposal of Undertaking: The net profit for the year increased due to the disposal of an undertaking situated at 11/12, 9 Sector E Sanwer Road Industrial Area, Indore M.P., to Formo Plast Private Limited, after obtaining member approval. [Non-Recurring]
  • Factory Renovation: Due to a revision in Schedule M (Drug & Cosmetics Rules), the factory is undergoing renovation and upgradation. Manufacturing operations were partially disrupted during the year, resulting in a decline in turnover compared to the previous year.
  • The figures for the quarters are balancing figures between the audited full year and the published unaudited year-to-date figures up to the third quarter.
  • The operations of the company are conducted within India; there is no separate reportable geographical segment.
  • Previous period/year figures have been re-stated/re-grouped/re-arranged/reclassified and/or recasted wherever necessary.